

2016 ISSDP Conference Program
 16th – 18th May 2016
 Quarantine Station, Manly NSW, Australia

Monday 16th May - Day One

8:00am – 9:00am	Registration			
9:00am - 9:30am	Opening Ceremony Welcome to Country Room P27			
9.45am -10.30am	Keynote Presentation: Professor Louisa Degenhardt “The epidemiology of illicit drug use and harm globally: An overview of recent findings” Chair: Alex Stevens Room P27			
10:30am - 11:00am	MORNING TEA			
Session Theme	Opioids and Prescription Drug Misuse Room P27	International policies Room P16	Harm Reduction Room H1	Drug Trade, Organised crime & violence Room H1B
Discussant chair	Michael Farrell	Beau Kilmer	Tim Rhodes	Caitlin Hughes
A 11:00am - 12:30pm	102. Utilisation and barriers to accessing opioid analgesics: A country, regional, and global study Stefano Berterame, Juliana Erthal, Johny Thomas, Sarah Fellner, Benjamin Vosse, <u>Philip Clare</u> , Wei Hao, David T. Johnson, Alejandro Mohar, Jagjit Pavadia, Ahmed Kamal Eldin Samakc, Werner Sipp, Viroj Sumyai, Sri Suryawati, Jallal Toufiq, Raymond Yans, Richard P. Mattick	Panel #1 Marginal Changes in International Drug Policies Panelists: Dr. John Collins Dr. Peter Reuter Dr. Aileen O’Gorman Dr. Daniel Bear Alexander Soderholm Aim: In February 2016, the LSE Expert Group on the Economics of Drug Policy will be releasing its new major report, ‘After the Drug Wars’, outlining the policy choices and metrics vital for the post-‘War on Drugs’ era. The report calls for prohibitionist policies to take a back seat to the new, comprehensive, people-centred set of universal and transformative goals and targets that we know as the Sustainable Development Goals (SDGs). Thus, the panel will examine the ways of making drug policy marginally more effective: discussing policing strategies at the different stages of illicit drugs markets and how these fit into national and international level strategies.	41. More than harm reduction: reflections from a qualitative research project in London, UK <u>Fay Dennis</u>	120. Outlaw Motorcycle Gangs (OMCGs) and the drug trade: The fallacy of Queensland’s anti-bikie laws and the implications both in Australia and overseas of using this model of crime management. <u>Terry Goldsworthy</u>
	29. Intertwined Epidemics: U.S. Regional Disparities in the Heroin and Opioid Overdose Epidemics Jay Unick, Sarah Mars, <u>Dan Ciccarone</u>		4. Peer engagement in harm reduction policy, practice, and research: A critical case study from British Columbia, Canada <u>Alissa Greer</u> , Luchenski, S., Amalni, A., Lacroix, K., Burmeister, C. & Buxton, J.A.	2. Political Determinants of Violence in the Metropolitan Area of Buenos Aires <u>Alberto Föhrig</u>
	111. Prescription drug misuse: a university-led harm reduction approach <u>Samuel Andrews</u>		127. Drug consumption rooms: evidence, narratives and policy replication <u>Vanessa Gstrein</u>	74. The Spillover Effects of the War on Drugs: Child Labor and Human Capital in Peru <u>Maria Micaela Sviatschi</u>
	16. Access to opioid medications in India: A confused and entangled policy framework <u>Atul Ambekar</u>		97. Engagement with drug users in an active street market: what difference does two decades make? <u>Peter Higgs</u>	67. How and Why do Drug Policies Alter Violence? Evidence from the Mexican Case <u>Laura Atuesta</u> , Aldo Ponce

12:30pm - 1:30pm

LUNCH

Monday 16th May - Day One

Session Theme	Drugs around the globe Room P27	Drug User Organising Room P16	Perspectives on Policy Room H1	CJS policies: international perspectives Room H1B
Discussant chair	Le Minh Giang	Lisa Maher and Mary Harrod	Mark Monaghan	Eric Sevigny
B 1:30pm - 3:00pm	130. War and Drugs: Japan's Drug Policy in Shanghai, 1937-45 Yong-an Zhang, <u>Yang Su</u>	Panel #2 Opportunities and challenges for drug user organising: Perspectives on periphery and partnership Panelists: Vibeke A. Frank, Esben Houborg, Jude Byrne, Annie Madden, Jenny Kelsall Aim: This session will discuss the history and evolution of drug user organising globally highlighting lessons learned internationally, nationally, and locally with a focus on Australia and Scandinavia. Presenters will review past successes and strengths, highlighting the important contributions drug user organisations make to drug policy, as well as key challenges facing drug user organising and drug user organisations in the current environment.	52. Addiction, dependence and questions of harm <u>Helen Keane</u>	11. Modelling the asymmetry of supply reduction and demand reduction in drug markets <u>Angela Me</u> , Antoine Vella
	49. The Abuse of Drug in Kenya <u>Gordon Ondiek Nyabade</u>		32. Assessing causality in drug policy analyses: how useful are the Bradford Hill criteria in analysing take-home naloxone programs? <u>David McDonald</u> , Anna Olsen, Simon Lenton, Paul Dietze	128. Comparing illicit drug policies on paper and in practice: the discrepancy between drug laws and their enforcement <u>Vendula Belackova</u> , Alison Ritter, Marian Shanahan, Caitlin Hughes,
	6. Illicit drug across Brazil: an overview of key use, harm and policy developments <u>Andrea Gallassi</u> , Maurício Fiore, Benedikt Fischer		129. Indexes used in the evaluation of alcohol and illicit drug policies <u>Vivienne Moxham-Hall</u> , Alison Ritter	83. 200 Years of Drug Policy in Thailand <u>Michael Cole</u>
			94. Polydrug use - A challenge to research and policy <u>Pekka Hakkarainen</u> and the MiksMix project	
3:00pm - 3:30pm	AFTERNOON TEA			

Monday 16th May - Day One

Session Theme	Cannabis Regulation Room P27	Evidence, media, politics Room P16	Hepatitis C treatment policy Room H1	e-cigarettes Room H1B
Discussant chair	Rob MacCoun	Alex Stevens	Paul Dietze	David McDonald
C 3:30pm - 5:00pm	20. Is the 'Saga of Promise, Hesitation & Retreat' really coming to an end? The prospects and evolving policy parameters of cannabis legalization in Canada <u>Benedikt Fischer</u>	76. Contesting and Contested Expertise: Influences on UK Drug Policy Mark Monaghan and <u>Emma Wincup</u>	Panel #3 Access and equity in a new era of hepatitis C treatment and care Panelists: Margaret Hellard David Iser Annie Madden Carla Treloar Aim: Direct acting antiviral (DAA) treatments for hepatitis C are highly efficacious, tolerable and short-duration treatments that are revolutionising policy related to injecting drug use. This panel discussion will describe the ways in which DAAs are transforming hepatitis C care policy and practice at global and local levels, making the prospect of HCV elimination real. This panel discussion will present a range of perspectives on new DAA treatments for hepatitis C, bringing together the reflections of leading community, clinical and social research stakeholders. Ultimately the panel discussion will aim to inform policy and practice considerations for ensuring high quality and equitable access to new hepatitis C therapies.	Panel #4 e-Cigarettes/Electronic Nicotine Delivery Systems and Drug Policy Panelists: Dr Coral Gartner Professor Ron Borland David McDonald Aim: The aim of this Panel is to develop a broader and deeper understanding of policy issues relating to electronic cigarettes/electronic nicotine delivery systems (ENDS) among participants of the Conference and, through doing so, better equip them to contribute to policy in this area within their own jurisdictions. Much is to be learned from exploring ENDS policy, and much of that learning can inform policy analyses and responses relating to other psychoactive substances. There are many reasons for this, including the fact that diverse regulatory models are being explored and implemented across the globe on a thin evidence base about their likely outcomes; and that policy in this area highlights the prohibition/regulation/free availability policy continuum that underpins substance use policy across the board
	124. Smoke and mirrors: issues relating to data collection and impact assessment in Colorado's recreational cannabis market <u>Todd Subritzky</u> , Simone Pettigrew, Simon Lenton	60. "Naloxone works": The politics of knowledge in overdose prevention and management policy <u>Kari Lancaster</u> ; Carla Treloar; Alison Ritter		
	30. From Toques to Tokes: The Challenges Facing Regulated Cannabis Sales in Canada <u>Daniel Bear</u>	13. Getting Voices to the Policy Table: the role of drug consumers and experiential knowledge in measurements of drug related harm. <u>Anna Ross</u>		
	105. When Drug Dealers Can Advertise: A discourse analysis of vendor product descriptions Judith Aldridge and <u>Rebecca Askew</u>	137. A critical discussion of Kingdon's approach to policy analysis: three moments of shifting policy in English drugs policy <u>Susanne MacGregor</u>		
5:15pm - 7:00pm	WELCOME RECEPTION (cash bar) The Boilerhouse – Q Station Lower Deck Area			

Tuesday 17th May - Day Two

8:30am – 9:00am	Registration			
9:00am - 9:45am	Keynote Presentation: Dr Le Minh Giang The politics of drug policy in the global Southeast Asia: A case study of Vietnam Chair: Carrie Fowlie Room P27			
9:45am - 10:45am	Plenary - The United Nations General Assembly Special Session (UNGASS) on Drugs: Reflections on Policy UNGASS 2016 provided an opportunity for a lengthy debate about the role of the international treaties in drug policy. In this plenary panel a number of experts will discuss the UNGASS Declaration and the processes. Margaret Hamilton will talk about civil society's involvement in UNGASS and their feelings about what came out of it. Tomáš Zábanský will discuss how individual governments engaged with the process. Angela Me will discuss the research and monitoring aspects of the UNGASS discussions. Chair: Peter Reuter Room P27			
10:45am - 11:15am	MORNING TEA			
Session Theme	Heroin Room P27	Medicinal Cannabis and Therapeutic Plants Room P16	Drug Treatment Room H1	Civil Society Room H1B
Discussant chair	Paul Dietze	Tom Decorte	Marian Shanahan	David McDonald
D 11:15am - 12:30pm	95. Predicting Attitudes toward Heroin-Related Harm Reduction and People Who Use Heroin <u>Perilou Goddard</u> , Sara M. Sharpe, Stefanie A. Kozlowski, Casey A. Crane, Cinnamon M. Schummer, and Jozie S. Banas	82. Human rights, public health and medicinal cannabis use <u>Melissa Bone</u> , Toby Seddon	110. Women-specific residential therapeutic community program In Iran: The first qualitative study from West Asia <u>Roya Noori</u> , Zahra Alam-Mehrjerdi, Babak Moazen, Nazgol Mostafavi Nasab	121. Safe nightlife policies, security assemblages and the reconfiguration of sovereignty in the Danish nightlife <u>Thomas Friis Søggaard</u> & Esben Houborg
	44. Social supply and 'hard' drugs: problematic users' experiences of crack and heroin markets in the UK <u>Gary R. Potter</u>	57. Observations of the role of science in the United States medical cannabis state policies: Lessons learnt <u>Jelica Grbic</u> , Perilou Goddard	104. Continuous Quality Improvement (CQI) in Substance Abuse Treatment Centers: How Much Does it Cost? <u>Priscillia Hunt</u>	88. Drugs, policy, politics and governance: The role of non-government organisations in Australian drug policy <u>Natalie Thomas</u>
	114. Social Transformation, Living Chance and Drug Control: An Empirical Study in Rural China Shaozhen Lin, <u>Yong-an Zhang</u>	31. Therapeutic and religious use of psychoactive plants: harm reduction and models of regulation integrating medical, ethnobotanical, and human rights considerations <u>Daniel Perkins</u> , Violeta Schubert	40. The Indonesia National Rehabilitation Movement: Where are we moving to? Riza Sarasvita, Mushlihah, <u>Eunike Sri Tyas Suci</u>	115. National Drug Policy of Turkey (Civil society's involvement in Turkish policy processes) <u>Savas Yilmaz</u>
12:30pm - 1:30pm	LUNCH			

Tuesday 17th May - Day Two

Session Theme	Vietnam and Drugs Room P27	Cannabis Potency and Regulation Room P16	Treatment Room H1	Cryptomarkets Room H1B
Discussant chair	Lisa Maher	Beau Kilmer	Annie Madden	David Décary-Héту
E 1:30pm - 3:00pm	<p>51. Drug and Drug Trafficking in the Greater Mekong Sub-regional: A Case Study of Vietnam and its Shared Borders</p> <p><u>Hai Thanh Luong</u></p>	<p>125. How to regulate Cannabis social clubs. Analyzing the experiences in Uruguay, Spain and Belgium</p> <p><u>Tom Decorte</u>, Mafalda Pardal, Rosario Queirolo, Maria Fernanda Boidi, Constanza Sanchez Aviles, Oscar Pares</p>	<p>36. Estimating population need for substance use services: A critical analysis of 35 years of research on expert and consumer perspectives</p> <p><u>Elaine Hyshka</u>, Gaju Karekezi, Benjamin Tan, Jesse Jahrig, Linda Slater, T. Cameron Wild</p>	<p>Panel #5 Cryptomarkets: harms, benefits, size and scope</p> <p>Panelists: Judith Aldridge Jack Cunliffe David Décary-Héту James Martin Masarah-Cynthia Paquet-Clouston Alex Stevens</p> <p>Aims: This panel brings together research that focuses on the online sales of illicit drugs in cryptomarkets. Panellists will cover an array of topics related to this emergent phenomenon that will be enhanced by their diversified origin (three continents) and their many research backgrounds. The aim of this panel is to develop our understanding of how cryptomarkets operate.</p>
	<p>71. "I am planning to get married but am not sure if she will accept my past [life]": Experiences of Drug Users and Their Families With Drug Policy Changes in Hai Phong, Vietnam</p> <p>Le Minh Giang, <u>Lung Bich Ngoc</u>, Pham Thi Thu Huyen, and Dinh Thi Thanh Thuy</p>	<p>59. De Palabras y Hechos: The Rhetoric and Reality of Cannabis Reform in Latin America (2008-2016)</p> <p><u>Jonas von Hoffmann</u></p>	<p>132. Cognitive-behavioral therapy as a treatment approach for regular methamphetamine use on methadone program: the first randomized, controlled trial</p> <p><u>Zahra Alam-mehrjerdi</u>, Philip Clare, Nadine Ezard, Kate Dolan</p>	
	<p>123. Economic Evaluation comparing Centre-based Compulsory Drug Rehabilitation with Community-based Methadone Treatment in Hai Phong City, Vietnam</p> <p><u>Thu Vuong</u>, Marian Shanahan, Nhu Nguyen, Giang Le, Robert Ali, Khue Pham, Thu T. A. Vuong, Thuy Dinh, Alison Ritter</p>	<p>38. Global Trends in Cannabis Potency: A Systematic Review and Meta-Regression</p> <p><u>Eric L. Seigny</u></p>	<p>136. Estimating treatment costs: discussing methods and key challenges</p> <p><u>Claudia Costa Storti</u> and Charlotte Davies</p>	
3:00pm - 3:30pm	<p>101. Official Images of Drug User in Vietnam Over the Past Five Decades: A Discourse Analysis</p> <p>Le Minh Giang, <u>Pham Thi Thu Huyen</u>, Dinh Thi Thanh Thuy and Pham Phuong Mai</p>	<p>107. SimSemilla: A Simulation Model of Marijuana Related Harms</p> <p><u>Robert MacCoun</u></p>	<p>12. Fear and freedom: examining the conflicting tensions inherent in the provision of pharmacotherapies in Australia</p> <p><u>Angella Duvnjak</u> and Jude Byrne</p>	
AFTERNOON TEA				
3:30pm - 4:15pm	<p>Keynote Presentation: Professor Simon Lenton "Being a Drug Policy Researcher – Why are we in the game and does that matter?" Chair: Beau Kilmer Room P27</p>			

Tuesday 17th May - Day Two

Session Theme	Opioid Prescription Room P27	Discrimination & policing Room P16	Modelling for drug policy Room H1	Older Drug Users Room H1B
Discussant chair	Chris Wilkins	Esben Houborg	Georgiy Bobashev	Susanne MacGregor
F 4:20pm - 5:30pm	22. Do More Robust Prescription Drug Monitoring Programs Reduce Prescription Opioid Overdose? A Quantitative Analysis. <u>Bryce Pardo</u>	62. Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego Emily F. Wood, Dan Werb, Leo Beletsky, Gudelia Rangel, Jazmine Cuevas Mota, Richard S. Garfein, Steffanie A. Strathdee, <u>Karla D. Wagner</u>	Panel #6 Mathematical and Simulation Modelling of Drug Policy Panelists: Shah Amal; Vu Lam; Georgiy Bobashev	Discussion group: Older Drug Users The UK Advisory Council on the Misuse of Drugs has set up a Working Group to explore specific issues relating to people in England aged over 35 years with a drug problem, especially those who have had a drug problem for an extended period of time. In this discussion, participants are invited to offer comments on appropriate policies and practices, especially based on experience in countries other than England. Examples of innovative responses are welcome.
	47. Rates of Opioid Overdose Among Recipients of US Disability Insurance Payments <u>George Unick</u> , Daniel Ciccarone	98. An Increase in Figures on Drug Offences in the Czech Republic: An Epidemic of Drug Crime or Something Else? <u>Petr Zeman</u> , Michaela Štefunková, Ivana Trávníčková	Aim: The aims are to highlight several roles of simulation modeling in understanding and evaluating drug policy. Because of the complex and adaptive nature of human response to policy low-dimensional linear statistical models might be inadequate.	
	46. Non-medical pharmaceutical opioid use among young people in Sydney <u>Kev Dertadian</u> , Lisa Maher	9. Drug policy practices in self-defense committees in Monzon, Peru and Community Police in Guerrero, Mexico. A Comparative Study <u>Angela Guerrero Alcantara</u>	We consider models that uncover hidden but critical trends in heroin initiation and spread, models for prescription opioid/heroin use, and models for life trajectories among drug users.	
5.45pm - 6.45pm	ISSDP Annual General Meeting Room H1			
7:00pm - 9:30pm	CONFERENCE DINNER (ticketed, cash bar) The Boilerhouse – Q Station Lower Deck Area			

Wednesday 18th May - Day Three

8:30am – 9:00am	Registration			
9:00am - 9:45am	Keynote Presentation: Professor Scott Burris “Comparative Drug Policy Research: Tools for a More Legalish Future” Chair: Peter Reuter Room P27			
Session Theme	Methamphetamines Room P27	Swift & certain sanctions Room P16	Policing Drugs Room H1	Global Legalisation Room H1B
Discussant chair	Tomáš Záborský	Angela Me	Claudia Costa Storti	Robin Room
G 9:50am - 11:00am	90. How is methamphetamine typically purchased and used in Melbourne, Australia? Reports from a cohort of people who inject drugs <u>Nick Scott</u> , Jonathan P Caulkins; Paul Dietze	50. Can Swift, Certain and Fair work in Urban Locales? <u>Greg Midgette</u>	70. An Investigative Study into the Knowledge and Perceptions of Illicit Drug Trafficking into and within Durban, KwaZulu-Natal, South Africa. <u>Livasha Moodley</u>	19. Transnational Social Movement Theory and International Drug Law Reform <u>Ben Mostyn</u>
	78. Australian border supply trends of meth/amphetamine 2002-2014: End-product and precursors <u>Matthew JA O'Reilly</u> , Caitlin E Hughes, Jenny Chalmers	18. Using certainty and celerity of sanction to produce specific deterrence: Individual-level insights from a large-scale implementation of the 24/7 Sobriety Program <u>Beau Kilmer</u> & Greg Midgette	84. The Bidirectional flow model of New Psychoactive Substance and legal responses in China <u>Minqi Zhao</u>	86. Drug Policies Reformation of Islamic Republic of IRAN (With the Approach of Freely Use of Natural Drug) <u>Mohammad Khezri</u> , Matin Anjomrooz
	54. Evaluation of the prevalence of consumption of methamphetamines in industrialized communities in Iran <u>Hooman Narenjiha</u> , Behzad Damari , Hamid Reza Khodami Vishteh ,Iraj Esmaili , Hamid reza sarami , Hosein Almadani , Farshid Alaeddini , Dorrin Narenjiha, Morvarid Narenjiha	23. The deterrent effects of Australian street-level drug law enforcement on illicit drug offending at outdoor music festivals <u>Caitlin Hughes</u> , Vivienne Moxham-Hall, Alison Ritter, Robert MacCoun, Don Weatherburn	75. Alternate policing strategies: Cost effectiveness of cautioning for cannabis offences <u>Marian Shanahan</u> , Caitlin Hughes, Tim McSweeney	42. Global Drug Policy Reform: Beyond the Rhetoric of Demand, Supply and Harm Reduction <u>Fay Hodza</u> & Portia Chiremba
11:00am - 11:20am	MORNING TEA			

Wednesday 18th May - Day Three

Session Theme	Harm Reduction Room P27	Decriminalisation across the globe Room P16	Substance use normalisation Room H1	Workshop Room H1B
Discussant chair	Carla Treloar	John Collins	Monica Barratt and Judith Aldridge	Beth Ann Griffin
H 11:20am - 12:50pm	118. Harm reduction policy across Canada: A descriptive analysis <u>T. Cameron Wild</u> , Donald MacPherson, Lynne Belle-Isle, Walter Cavalieri, Richard Elliott, Keely McBride, Bernie Pauly, Carol Strike, Kenneth Tupper, Caitlin Sinclair, Gaju Karekezi, Benjamin Tan, Mark Asbridge, Colleen Dell, Andrew Hathaway, Christopher Smith, Elaine Hyshka	48. Decriminalisation in Asia: principles and practices <u>Gloria Lai</u>	Panel #7 Substance use normalization: policy and research implications Panelists: Sharon R. Sznitman Cameron Duff Tom Decorte Aim: The aim of this panel is to discuss the implication of the drug normalization framework for research and policy. More specifically, the panel will provide the audience with a comprehensive overview of the normalization framework by providing a systematic and critical review of how researchers have applied the normalization framework to empirical research studies on substance use. The panel will also include a presentation of the implications of the normalization framework on harm reduction research and practices/policies. Finally, the panel will include a presentation of a novel application of the normalization framework that is used to interpret survey feedback comments by small scale cannabis growers.	Workshop State-of-the-art strategies for addressing selection bias when estimating the impact of drug policies, prevention programs, and treatments Presenter: Beth Ann Griffin Aim: The increased availability of observational data resulting from policies that require service providers, states and countries to collect data on client progress and policy impacts provide a data rich environment to test important hypotheses about the causal effects of drug policies, prevention programs, and drug treatments. In this statistical workshop, participants will learn 1. The core foundation for drawing causal inference about the impact of drug policies, prevention programs, and treatments; and 2). how to apply propensity score weighting methods to their own research involving two or more groups exposed to different drug policies, prevention programs, and treatments Dr. Griffin would like to utilize one or two case studies from drug policy research that workshop attendees are currently trying to tackle. If you have something that might be a good fit for the workshop, please email her at bethg@rand.org .
	96. Using in safe spaces: Factors affecting where women in Tijuana México who inject drugs and participate in sex work can inject drugs <u>Peter Davidson</u> , Priya Chakrabarti, Elí Abraham Andrade	126. Czech drug policy – quarter century of decriminalisation <u>Tomáš Záborský</u> , Josef Radimecky, Vendula Belackova		
	8. Worth the Test? Pill testing in the Australian drug policy context. <u>Andrew Groves</u>	72. From Hard to Soft Approach: A Parallel Transition in the Global Drug Policy and International Justice System <u>Majid Alaee</u> , Farangiss Bayat		
	64. Good samaritans vs. predatory peddlers: Problematizing the war on overdose in the US <u>Katherine McLean</u>	35. Legalizing Drug Use? Discernment and Contextualization in the Implementation of Liberal Drug Policies in Africa <u>Ediomo-Ubong Ekpo Nelson</u>		
12:50pm - 1:45pm	LUNCH (IJDP Editorial Board meeting, Room H1)			

Wednesday 18th May - Day Three

Session Theme	Power, inequality and drug policy Room P27	New Psychoactive Substances and Regulation Room P16	Drug Policy and the public good Room H1	Prevention and Training Room H1B
Discussant chair	Vibeke Asmussen Frank	Daniel Bear	Peter Reuter	Carrie Fowlie
1:45pm - 3:15pm	<p>Panel #8 Power, inequality and drug policy: European perspectives. Panel of the joint ISSDP/ESC Working Group on European drug policy</p> <p>Panelists: Jon Collins Esben Houborg Alex Stevens</p> <p>Aim: This panel aims to discuss how the distribution of power affects the development of drug policy, both at international and national level. It will use research papers on the historical role of Europe in the development of international drug policy and on the political economy of new drug strategies in Denmark and England to explore this topic.</p>	<p>87. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation</p> <p><u>Monica Barratt</u>, Kate Seear, Kari Lancaster</p>	<p>Panel #9 New Insights from revisions of "Drug Policy and the Public Good"</p> <p>Panelists: Benedikt Fischer Peter Reuter Robin Room</p>	<p>28. Exploring effective and holistic policy framework to protect children's future from alcohol marketing; Sri Lankan Perspective</p> <p><u>Rakhitha Asela Dissanayake</u></p>
		<p>77. "Lost in translation": issues with the establishment of a legal market for 'low risk' psychoactive products ('legal highs') in New Zealand</p> <p><u>Marta Rychert</u>, Chris Wilkins</p>	<p>Aim: Drug Policy and the Public Good, published in 2010 and co-authored by 12 senior scholars, was an effort to provide a comprehensive review of the scientific literature on the nature of global drug problems and on the effectiveness of interventions to reduce those problems.</p> <p>Since 2010, the scientific literature has developed rapidly in some areas. The three papers in this panel offer reviews of developments in three policy domains; prescription regimes, international drug control and supply control.</p>	<p>134. Implementation of the #Tamojuntto (Unplugged) drug prevention program in Brazilian schools: effectiveness and sustainability as a public policy</p> <p><u>Zila M Sanchez</u>; Adriana Sanudo; Daniela R Schneider</p>
		<p>27. Did the regulated legal market for synthetic cannabinoid products displace the illegal market for natural cannabis in New Zealand?</p> <p><u>Chris Wilkins</u>, Jitesh Prasad, Karl Parker, Marta Rychert</p>	<p>15. What works what does not work in measures against NPS? Similarities and differences in changing NPS market brought by new regulatory approaches in Eastern and Central European States</p> <p><u>Artur Malczewski</u>, A. Zile-Veisberga</p>	<p>17. Addiction Prevention Training Program Of Turkey (TBM)</p> <p><u>Azize Nilgün Canel</u></p>
3:20pm - 3:45pm	<p>Presentation: Senator Richard Di Natale, Leader of the Australian Greens "Applying drug policy in practice" Chair: Alison Ritter Room P27</p>			
3:45pm - 4:00pm	<p>Conference Closing Ceremony (Alison Ritter) and invitation to ISSDP 2017: Aarhus University, Denmark Room P27</p>			